Board of Directors At present, the Board of Directors of Exiqon A/S is composed of five members. The Board members’ business address is Exiqon A/S, Skelstedet 16, 2950 Vedbæk, Denmark.
A list of the members of the Board of Directors is set out below.
(born 1952, Danish citizen). Thorleif Krarup holds and has held a number of directorships in Danish, English and American listed companies. During the period 1985-2003, Thorleif Krarup served as Managing Director/Group CEO in Nykredit (1985-1992), Unibank (1992-2000) and Nordea (2000-2003).
(born 1949, Swedish citizen). Erik Walldén, President & CEO of Gyros AB and Chairman, Business and Finance Work Group, SwedenBIO. Erik Walldén has a record of achievement in the biotech industry for over 30 years. He has held senior management positions in companies such as Pharmacia LKB Biotechnology AB and PerSeptive Biosystems Inc. Erik Walldén was formerly the CEO of Pyrosequencing AB, Biacore International AB, and Affibody Holding AB.
(born 1956, Danish citizen). Michael Nobel was trained and employed with A.P.Møller between 1978 and 1983, after which time he became Export Manager with E. Nobel Cigar og Tobaksfabrikker A/S and Skandinavisk Tobakskompagni A/S. Michael Nobel is co-founder and chairman of the software company Medtime A/S.
(born 1947, Norwegian citizen). From 1976 to 1986 Per Wold-Olsen, MBA, was CEO of MSD Norway after which, in 1986, his field of responsibility was extended to MSD Scandinavia. In 1991, Per Wold-Olsen was appointed Senior Vice President for Worldwide Human Health Marketing of Merck & Co., Inc., U.S., and in 1994 he was appointed President for Human Health Europe Merck & Co., Inc., U.S. In 1997, his responsibilities for Human Health Europe were extended to include Eastern Europe, the Middle East and Africa, and Worldwide Human Health Marketing. In 2005, his field of responsibility was extended to include Latin America and Canada as President for Human Health Intercontinental Region, Merck & Co., Inc. From 1994 to 2006, Per Wold-Olsen was a member of Merck’s Management Committee. |